| 2002-04 |
Established Acugen Neuropeutics Inc. in Seattle, Washington, USA, to develop treatments for degenerative eye diseases and screening systems for pharmaceuticals. |
| 2003-03 |
Changed company name to Acucela Inc. |
| 2005-10 |
Initiated search for visual cycle modulators. |
| 2006-03 |
Relocated all departments, including headquarters and research facilities, to Bellingham, Washington, USA. |
| 2006-04 |
Commenced development of the visual cycle modulator 'Emixstat Sodium Salt' for retinal disease treatment. |
| 2006-08 |
Opened Acucela Inc. Japan office in Shinagawa-ku, Tokyo. |
| 2008-05 |
Submitted IND for 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration to the FDA. |
| 2008-06 |
Initiated Phase 1 clinical trial of 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration. |
| 2008-09 |
Entered joint development and joint sales agreement with Otsuka Pharmaceutical Co., Ltd. for our key compound 'Emixstat Sodium Salt'. |
| 2010-03 |
FDA designated 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration as Fast Track. |
| 2010-09 |
Relocated headquarters, including administration and clinical development divisions, to Seattle, Washington. |
| 2013-04 |
Initiated Phase 2b/3 clinical trials of 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration. |
| 2013-09 |
Moved Acucela Inc. Japan office to Shibuya-ku, Tokyo. |
| 2014-02 |
Listed on the Tokyo Stock Exchange Mothers market. |
| 2015-06 |
Announced results of Phase 2a clinical trial of 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration. |
| 2015-12 |
Established subsidiary Acucela Japan Co., Ltd. (now Kubota Pharmaceutical Holdings Co., Ltd.) in Shibuya-ku, Tokyo. |
| 2015-12 |
Established: December 2015 |
| 2015-12 |
Established |
| 2016-03 |
Acquired exclusive rights to develop cataract drug candidates from YouHealth. |
| 2016-04 |
Signed exclusive agreement with the University of Manchester for development and commercialization of gene therapy technology for retinal degenerative diseases. |
| 2016-05 |
Initiated Phase II clinical trial of 'Emixstat Hydrochloride' for proliferative diabetic retinopathy. |
| 2016-05 |
Announced results of Phase 2b/3 clinical trial of 'Emixstat Hydrochloride' for dry age-related macular degeneration with geographic atrophy. |
| 2016-06 |
Ended joint development and joint sales agreement for 'Emixstat Hydrochloride' with Otsuka Pharmaceutical Co., Ltd. |
| 2016-12 |
Implemented headquarter relocation to Japan via triangular merger, and Kubota Pharmaceutical Holdings Inc. made AcuSera Inc. a wholly-owned subsidiary. |
| 2016-12 |
Kubota Pharmaceutical Holdings Inc. listed on the Tokyo Stock Exchange Mothers market. |
| 2016-12 |
Entered into an option agreement with EyeMedics Inc. for exclusive rights to worldwide manufacturing, development, and sales of a new biomimetic technology. |
| 2017-01 |
FDA designated 'Emixstat Hydrochloride' for Stargardt disease as an orphan drug. |
| 2017-01 |
Initiated Phase 2a clinical trial of 'Emixstat Hydrochloride' for Stargardt disease. |
| 2017-02 |
Commenced in-house development of ophthalmic medical device solutions for home and remote care. |
| 2017-06 |
Relocated headquarters to Chiyoda-ku, Tokyo. |
| 2018-01 |
Signed joint development agreement with SIRION Biotech GmbH for gene delivery technology aimed at ophthalmic gene therapy research. |
| 2018-01 |
Announced results of Phase II clinical trial of 'Emixstat Hydrochloride' for proliferative diabetic retinopathy. |
| 2018-01 |
Announced results of Phase 2a clinical trial of 'Emixstat Hydrochloride' for Stargardt disease. |
| 2018-03 |
Initiated clinical trial of ophthalmic home and remote monitoring device 'PBOS'. |
| 2018-11 |
Announced results of clinical trial of ophthalmic home and remote monitoring device 'PBOS'. |
| 2018-11 |
Initiated Phase III clinical trial of 'Emixstat Hydrochloride' for Stargardt disease. |
| 2019-03 |
Signed contract to develop a small OCT (optical coherence tomography) device for NASA's deep space missions. |
| 2019-06 |
EMA designated 'Emixstat Hydrochloride' for Stargardt disease as an orphan drug. |
| 2020-04 |
Changed the trade name of wholly-owned subsidiary AcuSera Inc. to Kubota Vision Inc. |
| 2020-08 |
FDA selected Phase III clinical trial of 'Emixstat Hydrochloride' for Stargardt disease for the Orphan Products Clinical Trials Grants Program. |
| 2020-08 |
The wearable myopia device 'Kubota Glasses', aimed at suppressing and treating myopia progression, successfully completed a proof-of-concept (POC) test using wearable devices. |
| 2021-05 |
The wearable myopia device 'Kubota Glasses', aimed at suppressing and treating myopia progression, obtained a medical device manufacturing license in Taiwan. |
| 2021-10 |
Obtained ISO 13485:2016 international standard certification. |
| 2022-04 |
Kubota Pharmaceutical Holdings Co., Ltd. transitioned to the Growth Market segment of the Tokyo Stock Exchange. |
